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Introduction: The aim of this study was to define the frequency and associated clinical phenotype of anti-MDA5
autoantibodies in a large UK based, predominantly Caucasian, cohort of patients with juvenile dermatomyositis
(JDM).
Methods: Serum samples and clinical data were obtained from 285 patients with JDM recruited to the UK
Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-MDA5 antibodies was determined by
immunoprecipitation and confirmed by ELISA using recombinant MDA5 protein. Results were compared with
matched clinical data, muscle biopsies (scored by an experienced paediatric neuropathologist) and chest imaging
(reviewed by an experienced paediatric radiologist).
Results: Anti-MDA5 antibodies were identified in 7.4% of JDM patients and were associated with a distinct clinical
phenotype including skin ulceration (P = 0.03) oral ulceration (P = 0.01), arthritis (P <0.01) and milder muscle disease
both clinically (as determined by Childhood Myositis Assessment Score (P = 0.03)) and histologically (as determined
by a lower JDM muscle biopsy score (P <0.01)) than patients who did not have anti-MDA5 antibodies. A greater
proportion of children with anti-MDA5 autoantibodies achieved disease inactivity at two years post-diagnosis
according to PRINTO criteria (P = 0.02). A total of 4 out of 21 children with anti-MDA5 had interstitial lung disease;
none had rapidly progressive interstitial lung disease.
Conclusions: Anti-MDA5 antibodies can be identified in a small but significant proportion of patients with JDM
and identify a distinctive clinical sub-group. Screening for anti-MDA5 autoantibodies at diagnosis would be useful
to guide further investigation for lung disease, inform on prognosis and potentially confirm the diagnosis, as subtle
biopsy changes could otherwise be missed.Introduction
Autoantibodies can be detected in approximately 60% of
children with juvenile dermatomyositis (JDM) [1]. Anti-
MDA5 was initially identified in adult Japanese patients
with clinically amyopathic myositis and interstitial lung
disease (ILD), a phenotype more commonly seen in East-
Asia [1,2]. Studies based in East-Asia have identified anti-
MDA5 (anti-Melanoma differentiation associated gene 5)
autoantibodies in 19 to 35% of adult dermatomyositis* Correspondence: neil.mchugh@rnhrd.nhs.uk
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unless otherwise stated.(DM) patients [2,3], where it is associated with clinically
amyopathic myositis (81%), rapidly progressive ILD (74%)
and a poor prognosis [4,5]. Anti-MDA5 has been identi-
fied at a lower frequency in adult Caucasians [6-8], where
patients appear to have little myositis and an increased
risk of ILD, but not rapidly progressive ILD. Unlike in
East-Asian patients, in predominantly Caucasian adult po-
pulations a characteristic cutaneous phenotype has been
described, which includes skin ulceration and painful pal-
mar papules [2,6,8]. Patients can present with inflam-
matory arthritis, and similarities to the anti-synthetase
syndrome have been described [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be clearly established. A small Japanese study identified
anti-MDA5 in 38% of JDM patients, all of whom had
ILD, and three patients with very high titres of anti-
MDA5 had rapidly progressive ILD [9]. A further study
of 35 Japanese JDM patients demonstrated a significant
association between the presence of anti-MDA5 and the
development of rapidly progressive ILD [10]. Although
data on pulmonary involvement in JDM are limited, re-
ported rates of ILD in UK and USA patients with JDM
are far lower than in adult DM [11]. The incidence in
Japanese JDM populations, however, has been reported
to approach 50% [12]. This may reflect genetic and en-
vironmental differences or differences in autoantibody
prevalence (and therefore associated complications) be-
tween these populations. Here we report the clinical and
muscle histology associations of anti-MDA5 autoanti-
bodies in a large cohort of predominantly Caucasian pa-
tients with juvenile-onset myositis.
Methods
Patients
Patient serum samples and clinical data were obtained
through the UK Juvenile Dermatomyositis Cohort and
Biomarker Study (JDCBS). The JDCBS is a large cohort
of UK patients with myositis, the majority with JDM
[13]. Patients are recruited consecutively on presentation
to paediatric rheumatology departments across the UK,
and data are collected prospectively. Children and young
people aged 16 years or under are included based on a
diagnosis of definite or probable JDM or polymyositis by
Bohan and Peter criteria [14], as well as JDM, or poly-
myositis with overlapping connective-tissue disease fea-
tures. Biological specimens, including sera and muscle
biopsies, are collected and stored as described [13]. Ethical
approval has been obtained from the North Yorkshire
Multicentre Research ethics committee and this study
was also approved by the steering committee of the
JDCBS. Parental consent for children, and consent or
age-appropriate assent was obtained for all patients in
accordance with the declaration of Helsinki. Clinical
data were collected on standardised proformas: data items
in this analysis included demographics, the presence of
ulceration, oedema, calcinosis and/or arthritis during the
follow-up period, in addition to JDM disease activity
measures (childhood myositis assessment score (CMAS),
manual muscle testing score (MMT), serum creatinine
kinase, presence of skin disease and physician global visual
analogue score (PGAS). When available, muscle biopsy
samples and radiographic or computed tomography (CT)
images were analysed.
Remission in JDM was defined as a full-strength
CMAS >48 [15], the absence of skin disease (no rash,
Gottron’s papules, oedema, or ulceration) and a PGAS <1.Whilst this definition of remission has not been validated
all features listed are standard outcome measures in JDM.
Where possible we also utilised the recently proposed
Paediatric Rheumatology International Trials Organisation
(PRINTO) criteria for disease inactivity in JDM, de-
fined as at least three out of the four following cri-
teria; creatinine kinase ≤150, CMAS ≥48, MMT ≥78
and PGAS ≤0.2 [16].MSA detection
Serum or plasma was available from 285 patients. Sam-
ples were all stored at −80°C prior to analysis. Immuno-
precipitation of radiolabelled K562 cells was performed
to determine the presence of autoantibodies. The pres-
ence of anti-MDA5 was confirmed using ELISA.Immunoprecipitation
Sera (10 μl) was mixed with 2 mg protein-A-Sepharose
beads (Sigma, UK) in IPP buffer (10 mM Tris-Cl pH 8.0,
500 mM NaCl, 0.1% v/v Igepal) at room temperature for
30 minutes. Beads were washed in IPP buffer prior to
the addition of 120 μl (35S)methionine-labelled K562 cell
extract in IPP buffer. Samples were mixed at 4°C for 2 h.
Beads were washed in IPP buffer and TBS (10 mM Tris-Cl
pH 7.4, 150 mM NaCl) before being resuspended in
50 μl SDS sample buffer (Sigma, UK). After heating,
proteins were fractionated by 9% SDS-PAGE gels, en-
hanced, fixed and dried. Labelled proteins were ana-
lysed by autoradiography.ELISA
ELISAs were performed as previously described [2] with
some modifications: 96-well polystyrene plates were coated
with rMDA-5 (Origene, USA) at 4°C for 16 h. Serum sam-
ples were diluted to 1:250. Secondary antibodies were con-
jugated goat anti-human IgG/M antibodies (Sigma, UK).
Tetramethybenzidine liquid substrate (Sigma, UK) was then
added (10-minute incubation). All samples were tested in
duplicate and optical density was read at 450 nm using an
automatic plate reader. The negative cut off was defined
as >3 SD above the mean in serum from 34 normal healthy
(adult) controls.Indirect immunofluorescence
Indirect immunofluorescence was performed on HEp-2
cells (Immunoconcepts, USA) according to manufacturers’
instructions. Samples were diluted to 1 in 40.Immunoblot
Where ANA was positive, ENA (including anti-Ro52) were
looked for by immunoblot according to manufacturer’s in-
structions, (ANA profile 5, Euroimmun, Germany).
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Biopsies were processed, stained and scored using the
International JDM score tool as described [17]. All bi-
opsy scores were agreed by an experienced paediatric
neuropathologist (TSJ) who was blinded to autoantibody
and clinical data.
Pulmonary involvement
Where available, chest imaging obtained during routine
clinical care was reviewed by a single experienced thor-
acic radiologist (CO). Images were initially reviewed blind,
following which, clinical data were made available, includ-
ing pulmonary function tests (PFTs) and aspiration risk,
to assist with interpretation.
Statistical analysis
Statistical analysis was performed in SPSS. Potential dif-
ferences between two groups were assessed using Chi-
squared analysis with Yate’s continuity correction or
Fisher’s exact test for groups with small numbers. The
Mann-Whitney U-test was used to compare non-normally
distributed continuous data.
Results
Demographic data for the overall cohort and those with
anti-MDA5 are shown in Table 1. Anti-MDA5 autoanti-
bodies were identified in 7.4% of patients (21/285) and
did not co-exist with other myositis-specific or associated
autoantibodies. ANA was negative in 17 out of the 21 pa-
tients with anti-MDA5. The remaining four patientsTable 1 Demographic characteristics of the 285 patients
in this study
All JDM
patients,
n = 285
Anti-MDA5-
positive
patients, n = 21
Female, number (%) 206 (72) 15 (71)
Caucasian, number (%) 220 (78) 16 (76)b
Diagnosis, number (%)a
Dermatomyositis 242 (85) 21 (100)
Polymyositis 1 (0.4) 0
Overlap 33 (12) 0
Age at disease onset, years,
median (IQR)
6.3 (IQR 4 to 10) 6.6 (IQR 4 to 10)
Length of follow up, years,
median (IQR)
9 (IQR 5 to 12) 8 (IQR 5 to 11)
Highest ever CK, u/l,
median (IQR)
220 (IQR 111 to 1132) 129 (88 to 157)
aNine patients were classified as having focal myositis or other idiopathic
inflammatory myopathy; bOne Black-African patient, one Indian patient, one
Pakastani patient and two patients from other ethnic groups. All anti-MDA5
autoantibody-positive patients had juvenile dermatomyositis (JDM). Otherwise,
demographic data did not differ significantly between anti-MDA5 antibody
positive patients and the overall cohort. IQR, interquartile range; CK,
creatine kinase.had a non-specific, fine-speckle, nucleolar-sparing ANA
pattern. This pattern can be consistent with the presence
of anti-Ro52, although anti-Ro52 was not present on
immunoblot.
Cutaneous and joint disease
Anti-MDA5 autoantibodies were significantly associated
with the occurrence of both skin ulceration (52% anti-
MDA5 positive versus 27% anti-MDA5 negative, P =
0.03) and oral ulceration (71% anti-MDA5 positive ver-
sus 45% anti-MDA5 negative, P = 0.01) occurring at any
time point during the follow-up period but not with
oedema or calcinosis. As expected the large majority of
all the JDM cases (76%) had Gottron’s papules and/or
heliotrope rash (85%), but there were no significant asso-
ciations between presence of anti-MDA5, and Gottron’s
papules or heliotrope rash. Despite the association with
skin ulcerations we noted that no child with anti-MDA5
autoantibodies had a history of bowel vasculitis. There
were more children with arthritis in the anti-MDA5-
positive group: 86% of those with anti-MDA5 autoanti-
bodies had arthritis compared to 51% of those without
(P <0.01). In those with anti-MDA5 and arthritis 46%
had symmetrical polyarthritis involving the small joints
of the hands.
Muscle disease
The CMAS was used to assess muscle strength. Overall
the lowest recorded CMAS was significantly higher (P =
0.03) in those with anti-MDA5 compared to the rest of
the cohort, indicating less severe weakness (Table 2). A
CMAS of 48 or above has previously been demonstrated
to correspond to no significant functional weakness [15].
The presence of normal muscle enzymes (CK and lactate
dehydrogenase (LDH)) and a lowest recorded CMAS ≥48
was significantly associated with anti-MDA5 antibo-
dies (12.5% anti-MDA5-positive versus 1.2% anti-MDA5-
negative, P = 0.05).
Muscle biopsies were available for 11 patients with
anti-MDA5. These 11 biopsies, plus 30 others (randomly
selected from JDM patients without anti-MDA5 auto-
antibodies) were scored using the previously published
and validated JDM biopsy score tool, (Table 2) [17,18].
This tool assesses severity of pathological change in four
domains (inflammatory, muscle fibre, vascular, connec-
tive tissue), leading to an overall score, and a score of 0
to 10.0 on a visual analogue scale (VAS) for assessment
of severity [17,18].
Mean total biopsy scores and VAS scores for severity
were significantly lower in those with anti-MDA5, (both
P <0.001). The difference in total biopsy scores between
the two groups lay in a more destructive histological pat-
tern in the non-anti-MDA5 group with significant dif-
ferences in score within all four domains (inflammatory,
Table 2 Muscle disease in those with anti-MDA5
Anti-MDA5 autoantibody-positive Anti-MDA5 autoantibody-negative
Muscle strength
Median lowest ever recorded CMAS (IQR)a 46 (38 to 52) 40 (27 to 48)
Muscle histology
Median biopsy score (IQR) (17)b Inflammatory (0 to 12)c 2 (2 to 4.8) 7 (5.5 to 9.5)
Vascular (0 to 3)c 0 (0 to 0) 1 (0 to 2)
Muscle fibre (0 to 10)c 2 (1, 2) 7 (4 to 9)
Connective tissue (0 to 2)c 0 (0 to 0) 1 (0 to 1)
Total (0 to 27)c 4 (3.25 to 8.5) 15 (12.5 to 21)
VAS severity (0 to 10)c 2 (2) 5 (3.6 to 8)
a.P = 0.03; bbiopsies were analysed from 11 patients with anti-MDA5 autoantibodies and 30 without; cP <0.005. Patients with anti-MDA5 had less muscle
involvement, both clinically, as measured by the childhood myositis assessment score (CMAS) and histologically, as quantified by the juvenile dermatomyositis
(JDM) muscle biopsy scoring tool. VAS, visual analogue scale.
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connective tissue, P <0.003).
Pulmonary disease
Chest imaging had been performed in 12 patients with
anti-MDA5 and 9 had imaging studies available for re-
view (7 patients with CT and 2 with radiographs). Three
patients had chest radiographs previously reported as
showing no abnormality; these were not available to re-
review. As chest imaging was performed as part of rou-
tine care it was variably timed post diagnosis (up to 68
months). A request for imaging generally coincided with
either time of diagnosis or when the patient reported re-
spiratory symptoms. No patients with abnormal PFTs
went on to have high-resolution computed tomography
(HRCT).
Two patients, both aged 8 years at diagnosis, had def-
inite radiological changes consistent with ILD (as de-
monstrated on HRCT performed at 16 and 27 months
post diagnosis). Both patients had abnormal PFTs, al-
though in the later test, forced expiratory volume at 1 s
(FEV1) and forced vital capacity (FVC) were only slightly
reduced (78 and 86% predicted respectively) despite ex-
tensive changes on HRCT. DLCO was not performed.
Two further patients aged 4 and 2 years at diagnosis had
abnormal imaging probably consistent with ILD; one
with ground-glass changes on chest radiography but
with no further imaging or PFTs performed, and one
with extensive reticular changes on CT with radiologic
appearances consistent with ILD, aspiration and/or in-
fection. For the latter patient, taken in the clinical con-
text this was felt most likely to represent ILD. The
incidence of ILD in this group, therefore, appears to lie
between 10 and 19%, although this may be an underesti-
mate as nine patients had no chest imaging available,
and for some patients the available imaging was per-
formed many months post diagnosis.Where ILD was demonstrated the radiological appear-
ance was consistent with non-specific interstitial pneu-
monia and some patients had elements of organising
pneumonia. Histology was not available to confirm the
disease pattern. Of the two patients with definite ILD
on imaging, both had follow-up images available, which
demonstrated significant radiological improvement fol-
lowing treatment with intravenous cyclophosphamide.
Disease outcome
Disease outcome was assessed at 2 years (range 20 to
28 months) post diagnosis and again at the last clinic
visit, where this occurred 4 or more years post diagnosis,
(mean 7.1 years in the anti-MDA5-positive group and
7.9 years in the anti-MDA5-negative group). Data were
not yet available at 2 years post diagnosis when children
had been diagnosed with JDM less than two years previ-
ously, had been recruited into the study more than 20
years post diagnosis or had not been reviewed between
20 and 28 months post diagnosis. Information was avail-
able for 151 of 285 (53%) children at 2 years post diag-
nosis (12 with anti-MDA5) and 136 children (48%) at
more than 4 years post diagnosis (9 with anti-MDA5
autoantibodies).
Using a modified definition of remission, (full strength
CMAS of >48 [15], the absence of skin disease and a
PGAS <1), more patients with anti-MDA5 were in re-
mission 2 years post-diagnosis (P = 0.04) than those
without MDA5 autoantibodies, and there was a trend
for more of those with anti-MDA5 to be off all me-
dication at 2 years post diagnosis (P = 0.07). We also
analysed disease activity using the recently proposed
PRINTO definition of disease inactivity in JDM [16].
Despite smaller numbers with complete data for this
analysis, the results were concordant, with more chil-
dren with anti-MDA5 autoantibodies in remission at
2 years post diagnosis (P = 0.02), Table 3.
Table 3 Outcome at 2 and >4 years post diagnosis for affected children with and without anti-MDA5 antibodies
Two years post diagnosis More than four years post diagnosisa
Anti-MDA5 present Anti-MDA5 absent Anti-MDA5 present Anti-MDA5 absent
Inactive disease 6 (50%)b 30 (22%) 6 (66.6%) 59 (46%)
Active disease 6 (50%)b 109 (78%) 3 (33.3%) 68 (54%)
PRINTO inactive disease 7 (87%)b 44 (43%) 4 (100%) 51 (71%)
PRINTO active disease 1 (13%)b 59 (57%) 0 (0%) 21 (29%)
Results are presented as number of patients (%). aAverage 7.1 years anti-MDA5-positive and 7.9 years in anti-MDA5-negative; bP <0.05. Inactive disease is defined
as childhood myositis assessment score (CMAS) >48, absent skin disease and physician global assessment score (PGAS) <1. Paediatric Rheumatology International
Trials Organisation (PRINTO) criteria for inactivity is defined as at least three of the following; creatinine kinase (CK) ≤150, CMAS ≥48, manual muscle testing
score ≥78 and PGAS ≤0.2. Patients with anti-MDA5 were more likely to have inactive disease at the time points analysed. This was statistically significant at 2 years
post diagnosis.
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with ulceration and ILD, which are both considered to
be features of severe disease, we investigated whether
these patients were more likely to be targeted for aggres-
sive treatment. Slightly more patients with anti-MDA5
had received cyclophosphamide treatment than those
without but this difference was not significant, with 29%
compared to 21% of those without. Likewise no signifi-
cant difference was seen in the proportion receiving
methotrexate treatment (90% of those with anti-MDA5
versus 93% without). At 4 or more years post diagnosis
no statistically significant difference in disease activity
was seen but more children with anti-MDA5 had in-
active disease (Table 3).
Discussion
The identified prevalence of anti-MDA5 in 7.4% of the
patients should be considered a minimum, as whilst the
earliest available serum sample was used for autoanti-
body detection, this was often months post diagnosis.
Sato et al. demonstrated a fall in anti-MDA5 titre in re-
sponse to treatment and it is therefore possible that
some autoantibody-negative patients in our cohort were
treated patients with anti-MDA5 [19].
Anti-MDA5 autoantibodies were first described in
adults with amyopathic myositis and rapidly progressive
ILD: amyopathic myositis is recognised in children but it
is rare, and more often patients have mild or progressive
muscle disease [20,21]. We have previously shown that
histological features on biopsy are very mild in cases of
amyopathic JDM, and include absence of upregulation of
major histocompatibility complex (MHC) class I protein,
which is usually found in JDM biopsy tissue from more
typical cases [22]. The data presented here suggest that
in JDM anti-MDA5 antibodies are associated with mild
muscle involvement, both clinically and histologically.
To our knowledge this is the first report of quantitative
biopsy scoring in an autoantibody-specific subgroup and
suggests that in addition to clinical phenotype, autoanti-
bodies may also reflect variations in underlying muscle
pathology.Similar to previous studies in US and European adults,
anti-MDA5 autoantibodies are associated with less se-
vere muscle disease and a characteristic cutaneous phe-
notype, and in particular, ulcerative skin disease [6,23].
Whilst skin ulceration is generally considered one of the
most severe cutaneous manifestations of JDM, there was
no significant association with other severe cutaneous
disease features, such as oedema or calcinosis. The asso-
ciation with arthritis and anti-MDA-5 antibodies has
also been described in US adults [6,8]: in one study sev-
eral adult patients had even initially been suspected to
have rheumatoid arthritis [8]. Although we did not ana-
lyse disease presentation in this study, it seems likely
that some juvenile patients could be similarly misclassi-
fied. We suspect that this sub-group of patients may
often present as a diagnostic conundrum with rash, ul-
ceration and polyarthritis but minimal muscle disease.
Anti-MDA5 autoantibodies have been associated with
a poor prognosis in adult East-Asian cohorts due to the
association with rapidly progressive ILD [4,24]. This has
also been described in Japanese juvenile-onset patients
with anti-MDA5 [9]. In our cohort, 19% of those with
anti-MDA5 had radiological evidence of ILD. A large US
study of clinical phenotype of juvenile myositis patients
reported an incidence of ILD of 4.8% in those with JDM
[25]. Anti-MDA5 antibodies in our cohort were mutually
exclusive and specifically no patient had additional anti-
synthetase antibodies. It thus appears highly probable
that anti-MDA5 is associated with ILD in JDM: larger
future studies will be required to confirm this.
One limitation of this study is that not all of the cases
in this study had chest imaging available to review and
where imaging was available this was often some months
post diagnosis and following treatment. Furthermore, ra-
diograhy is an insensitive tool in excluding ILD, and ap-
proximately 10% of patients with ILD detected on HRCT
have a normal chest radiograph, especially early in the dis-
ease [26]. While our estimates of the prevalence of ILD in
the anti-MDA5 subpopulation may therefore be an under-
estimate, particularly if some children have mild ILD,
which responds to standard therapies, it does accurately
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tine clinical practice. A retrospective study of pulmonary
outcome in JDM in a Norwegian population reported a
previous diagnosis of ILD in 3 out of 59 patients (5%), one
of whom was known to have anti-Jo1 antibodies [27]. A
further four patients, however, were identified as having
evidence of ILD on subsequent HRCT. Anti-MDA5 an-
tibody status was not reported but interestingly these
four patients all had arthritis and skin ulcers [27]. Anti-
synthetase autoantibodies, which are associated with ILD,
are rare in JDM. Interestingly, of the six patients in our
cohort with anti-synthetase autoantibodies, four had evi-
dence of ILD, suggesting that they confer a greater risk of
developing ILD than anti-MDA5, although the incidence
in those with anti-Jo-1 autoantibodies (three patients) was
similar (33%).
Our findings also highlight the relative infrequency of
chest imaging by CT in children with JDM, in the UK,
in part secondary to concerns with regard to radiation
exposure and the perceived low incidence of lung dis-
ease. Assessment for the presence of anti-MDA5 auto-
antibodies would be useful to help target patients in
whom careful repeat chest imaging may be recommended.
This would be particularly valuable in patients diagnosed
at a young age, when PFTs cannot be performed.
Importantly and similar to adult Caucasian patients
with anti-MDA5 [6,8], no patients had rapidly prog-
ressive ILD. Furthermore, the response to treatment ap-
peared to be good with significant improvement seen on
follow-up imaging where this was available.
Interestingly, despite associations with ulceration and
probably ILD, both considered poor prognostic features,
significantly more children with anti-MDA5 were in re-
mission at 2 years post diagnosis than the rest of the
cohort.
At present diagnostic testing for anti-MDA5 is avail-
able at a limited number of centres worldwide. Standard
laboratory techniques, including indirect immunofluor-
escence, are of limited benefit and are likely to provide
negative or non-specific results. Whilst one study did
report a granular/reticular cytoplasmic speckle in anti-
MDA5 positive patients [28] this has not been our ex-
perience and may depend on the exact technique used.
Furthermore, this pattern is non-specific and may not be
reported by many laboratories. An association between
anti-Ro52 and anti-MDA5 has been noted in two adult
studies [6,8]. We did not identify co-existent anti-Ro52
autoantibodies in any of our patients with anti-MDA5.
There is growing interest in more widespread testing for
myositis-specific autoantibodies using standard labora-
tory techniques: line blot kits, which include anti-MDA5,
have been developed and will shortly be commercially
available. We anticipate that in the future testing for
the presence of anti-MDA5 autoantibodies where JDM orJDM overlap-syndromes are suspected will become stand-
ard clinical practice.
Conclusion
Anti-MDA5 autoantibodies can be identified in a
small but significant proportion of UK patients with
JDM. The particular clinical phenotype of this sub-
group is similar to that described in predominantly
Causcasian adult cohorts but appears to differ from
that described in East-Asian populations. The identi-
fication of anti-MDA5 at diagnosis would be useful
to guide further investigation for possible lung dis-
ease, inform on prognosis and potentially to confirm
the diagnosis, as subtle biopsy changes could other-
wise be missed.
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